IAG’s Jon Himoff named to CIO 100 UK 2026

Image Analysis Group Chief Product Officer Jon Himoff has been named one of the CIO 100 UK 2026 honorees, recognizing his work leading product, technology and AI strategy at IAG. The award spotlights DYNAMIKA™, IAG’s imaging clinical trials platform, as the company pushes a cloud-native, enterprise approach to trial imaging.

Why it matters: - The CIO 100 UK list recognizes technology leaders whose work has measurable business impact. - Himoff’s selection puts a spotlight on IAG’s role in imaging clinical trials, where platform design can affect speed, data quality and regulatory readiness. - The recognition also reinforces DYNAMIKA™ as a core part of IAG’s clinical development offering.

What happened: - Jon Himoff, Chief Product Officer at Image Analysis Group, was named in the CIO 100 UK 2026. - CIO UK and Foundry run the list of 100 of the UK’s most innovative and impactful technology leaders. - The winners were announced Sept. 24, 2026, at the CIO 100 Awards Ceremony and Dinner at The Royal Lancaster in London. - Himoff leads product, technology and AI strategy at IAG. - That remit includes DYNAMIKA™, IAG’s proprietary platform for imaging clinical trials.

The details: - Sponsors use DYNAMIKA™ to assess whether new drugs are safe and effective and to build evidence for regulatory approval. - In a sponsored feature in The Clinical Trial Vanguard, IAG described DYNAMIKA™ as an enterprise platform designed and built from the ground up for imaging clinical trials. - The platform runs on cloud-native infrastructure. - DYNAMIKA™ covers the full trial lifecycle, from site qualification and first test image upload through database lock. - Automated quality control checks each image at upload. - The system flags protocol deviations before they enter the dataset. - Examples include the wrong echo time or a scanner model that is not on the approved list. - Sponsors receive that alert the same day instead of waiting for interim analysis. - DYNAMIKA™ uses one shared infrastructure across a sponsor’s studies, sites and readers instead of separate trial instances. - Site performance history, reader calibration records and QC rules carry forward from one study to the next. - The platform is GxP-validated, SOC 2 Type II and 21 CFR Part 11-compliant. - DYNAMIKA™ supports imaging endpoints in oncology, obesity and metabolic disease, rheumatology and musculoskeletal disease, neurology and other therapeutic areas. - IAG says the platform helps sponsors start trials and lock databases faster, see progress in near real time, deliver clean data for regulatory submissions and recruit patients more quickly. - IAG says it has supported more than 700 clinical trials worldwide over nearly 20 years.

Between the lines: - The award validates more than individual leadership. It also signals market interest in infrastructure that can unify imaging trial operations across programs. - IAG’s emphasis on a single shared platform suggests an effort to move sponsors away from siloed trial management and toward reusable operational data. - That positioning matters because imaging trials are tightly linked to regulatory outcomes, and faster QC can reduce delays downstream. - Himoff framed the recognition as a team result, crediting product, engineering, QA, compliance and support staff.

What’s next: - IAG says DYNAMIKA™ will continue to support imaging clinical trials across therapeutic areas. - The company points readers to the full article in The Clinical Trial Vanguard for more on the platform’s operating model. - The CIO 100 UK awards page will remain the place to see the complete 2026 winner list.

The bottom line: - The award gives IAG external validation at a time when clinical trial sponsors are looking for faster, more integrated imaging workflows.